Kroatia - kroatisk - HALMED (Agencija za lijekove i medicinske proizvode)

alcon farmaceutika d.o.o., zagreb - elektrokirurški instrument koji se koristi prilikom kirurških operacija u oftalmologiji

Kroatia - kroatisk - HALMED (Agencija za lijekove i medicinske proizvode)

alcon farmaceutika d.o.o., zagreb - pribor koji se koristi uz accurus za kirurške zahvate u oftalmologiji

Kroatia - kroatisk - HALMED (Agencija za lijekove i medicinske proizvode)

optinova d.o.o., zagreb - laserski sustav za primjenu u oftalmologiji pri operacijama na prednjem segmentu oka

Kroatia - kroatisk - HALMED (Agencija za lijekove i medicinske proizvode)

novamed d.o.o., zagreb - šivanje i/ili postavljanje ligatura u mekom tkivu uključujući postupke u općoj kirurgiji i oftalmologiji

Bosnia-Hercegovina - kroatisk - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

pfizer bh d.o.o. - doksiciklin - tableta za oralnu suspenziju - 100 mg/1 tableta - 1 tableta za oralnu suspenziju sadrži: 100 mg doksiciklin (u obliku doksiciklin monohidrata)

Kroatia - kroatisk - HALMED (Agencija za lijekove i medicinske proizvode)

krka - farma d.o.o., radnička cesta 48, zagreb, hrvatska - natrijev deksametazonfosfat - otopina za injekciju / infuziju - 4 mg/ml - urbroj: 1 ml otopine za injekciju/infuziju (1 ampula) sadrži 4 mg deksametazonfosfata u obliku natrijeve soli

Kroatia - kroatisk - HALMED (Agencija za lijekove i medicinske proizvode)

cis bio international, rn 306, bp 32 - saclay, gif-sur-yvette, francuska - natrijev molibdat (99mo) natrijev pertehnetat [99mtc] fisijski pripravljen, injekcija - generator radionuklida - urbroj: generator radionuklida sadrži 2,5/5/7/9,5/12/14,5/19/24/30 ili 60 gbq molibdena [99mo] (u obliku natrijevog molibdata) na dan i sat umjeravanja iz kojeg se ispiranjem dobiva 2/4/6/8/10/12/16/20/25 ili 50 gbq tehnecija [99mtc] (u obliku natrijevog pertehnetata) na dan i sat umjeravanja.

Den europeiske union - kroatisk - EMA (European Medicines Agency)

amgen europe b.v. - adalimumab - arthritis, psoriatic; colitis, ulcerative; arthritis, juvenile rheumatoid; spondylitis, ankylosing; psoriasis; crohn disease; arthritis, rheumatoid - imunosupresivi - rheumatoid arthritis  amgevita in combination with methotrexate, is indicated for: , the treatment of moderate to severe, active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs including methotrexate has been inadequate. tretman teških, aktivnog i uznapredovalog reumatoidnog artritisa kod odraslih, ne ranije liječenih metotreksat. ,  amgevita can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. amgevita smanjuje brzinu progresije oštećenja zglobova kao što se mjeri x-ray i poboljšava fizičke funkcije, imenovanje u kombinaciji s metotreksatom. juvenile idiopathic arthritis polyarticular juvenile idiopathic arthritis amgevita in combination with methotrexate is indicated for the treatment of active polyarticular juvenile idiopathic arthritis, in patients from the age of 2 years who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (dmards). amgevita može biti dano kao monoterapija u slučaju netolerancije метотрексата ili pri stalnom liječenju s metotreksat je nepraktično (na učinkovitost u monoterapija vidi odjeljak 5. Адалимумаб ne ima dugu povijest u bolesnika u dobi od manje od 2 godine. enthesitis-related arthritis amgevita is indicated for the treatment of active enthesitis-related arthritis in patients, 6 years of age and older, who have had an inadequate response to, or who are intolerant of, conventional therapy (see section 5. axial spondyloarthritis ankylosing spondylitis (as) amgevita is indicated for the treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy. axial spondyloarthritis without radiographic evidence of as amgevita is indicated for the treatment of adults with severe axial spondyloarthritis without radiographic evidence of as but with objective signs of inflammation by elevated crp and/or mri, who have had an inadequate response to, or are intolerant to non-steroidal anti-inflammatory drugs. psoriatic arthritis amgevita is indicated for the treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying anti-rheumatic drug therapy has been inadequate. amgevita smanjuje brzinu progresije periferne lezije zgloba, mjereno pomoću x-zraka u bolesnika s полиартикулярным mogućnost simetrične podtipovi bolesti (vidi odjeljak 5. 1) i poboljšava fizičke značajke. psoriasis amgevita is indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who are candidates for systemic therapy. paediatric plaque psoriasis amgevita is indicated for the treatment of severe chronic plaque psoriasis in children and adolescents from 4 years of age who have had an inadequate response to or are inappropriate candidates for topical therapy and phototherapies. hidradenitis suppurativa (hs) amgevita is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults and adolescents from 12 years of age with an inadequate response to conventional systemic hs therapy (see sections 5. 1 i 5. crohn’s disease amgevita is indicated for treatment of moderately to severely active crohn’s disease, in adult patients who have not responded despite a full and adequate course of therapy with a corticosteroid and/or an immunosuppressant; or who are intolerant to or have medical contraindications for such therapies. paediatric crohn's disease amgevita is indicated for the treatment of moderately to severely active crohn's disease in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including primary nutrition therapy and a corticosteroid and/or an immunomodulator, or who are intolerant to or have contraindications for such therapies. ulcerative colitis amgevita is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine (6-mp) or azathioprine (aza), or who are intolerant to or have medical contraindications for such therapies. uveitis amgevita is indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients who have had an inadequate response to corticosteroids, in patients in need of corticosteroid-sparing, or in whom corticosteroid treatment is inappropriate. paediatric uveitis amgevita is indicated for the treatment of paediatric chronic non-infectious anterior uveitis in patients from 2 years of age who have had an inadequate response to or are intolerant to conventional therapy, or in whom conventional therapy is inappropriate.

Den europeiske union - kroatisk - EMA (European Medicines Agency)

amgen europe b.v. - adalimumab - arthritis, psoriatic; spondylitis, ankylosing; crohn disease; colitis, ulcerative; hidradenitis suppurativa; psoriasis; arthritis, rheumatoid - imunosupresivi - molimo pogledajte odjeljak 4. 1 sažetak značajki proizvoda u dokumentu o informacijama o proizvodu.

Den europeiske union - kroatisk - EMA (European Medicines Agency)

boehringer ingelheim international gmbh - adalimumab - hidradenitis suppurativa; arthritis, psoriatic; psoriasis; crohn disease; arthritis, juvenile rheumatoid; uveitis; arthritis, rheumatoid; colitis, ulcerative; spondylitis, ankylosing - imunosupresivi - molimo pogledajte odjeljak 4. 1 sažetak značajki proizvoda u dokumentu o informacijama o proizvodu.